These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 32089398)

  • 61. Insights into the pathogenesis of GvHD: what mice can teach us about man.
    Hülsdünker J; Zeiser R
    Tissue Antigens; 2015 Jan; 85(1):2-9. PubMed ID: 25532439
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Haploidentical hematopoietic transplantation for the cure of leukemia: from its biology to clinical translation.
    Mancusi A; Ruggeri L; Velardi A
    Blood; 2016 Dec; 128(23):2616-2623. PubMed ID: 27697774
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Alpha-1 Antitrypsin-Expressing Mesenchymal Stromal Cells Confer a Long-Term Survival Benefit in a Mouse Model of Lethal GvHD.
    Geiger S; Ozay EI; Geumann U; Hereth MK; Magnusson T; Shanthalingam S; Hirsch D; Kälin S; Günther C; Osborne BA; Tew GN; Hermann FG; Minter LM
    Mol Ther; 2019 Aug; 27(8):1436-1451. PubMed ID: 31138510
    [TBL] [Abstract][Full Text] [Related]  

  • 64. First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4+CD25+CD127- T regulatory cells.
    Trzonkowski P; Bieniaszewska M; Juścińska J; Dobyszuk A; Krzystyniak A; Marek N; Myśliwska J; Hellmann A
    Clin Immunol; 2009 Oct; 133(1):22-6. PubMed ID: 19559653
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Phase II Multicenter, Randomized, Double-Blind Controlled Study of Efficacy and Safety of Umbilical Cord-Derived Mesenchymal Stromal Cells in the Prophylaxis of Chronic Graft-Versus-Host Disease After HLA-Haploidentical Stem-Cell Transplantation.
    Gao L; Zhang Y; Hu B; Liu J; Kong P; Lou S; Su Y; Yang T; Li H; Liu Y; Zhang C; Gao L; Zhu L; Wen Q; Wang P; Chen X; Zhong J; Zhang X
    J Clin Oncol; 2016 Aug; 34(24):2843-50. PubMed ID: 27400949
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Modulation of acute graft-versus-host disease and chimerism after adoptive transfer of in vitro-expanded invariant Valpha14 natural killer T cells.
    Kuwatani M; Ikarashi Y; Iizuka A; Kawakami C; Quinn G; Heike Y; Yoshida M; Asaka M; Takaue Y; Wakasugi H
    Immunol Lett; 2006 Jul; 106(1):82-90. PubMed ID: 16806496
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Regulatory T cell immunotherapy for transplantation tolerance: step into clinic.
    Jiang S; Tsang J; Tam P
    Int Immunopharmacol; 2010 Dec; 10(12):1486-90. PubMed ID: 20736096
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [Mesenchymal stem cells for treatment of steroid-resistant chronic graft-versus-host disease].
    Zhang LS; Liu QF; Huang K; Zhang Y; Fan ZP; Huang SL
    Zhonghua Nei Ke Za Zhi; 2009 Jul; 48(7):542-6. PubMed ID: 19957792
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Ex vivo expansion of regulatory T cells for clinical applications against graft-versus-host disease in allogeneic hematopoietic stem cell transplantation.
    Zhang LF; Xia CQ
    Chin Med J (Engl); 2013 Dec; 126(23):4575-82. PubMed ID: 24286428
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Pharmacologic expansion of donor-derived, naturally occurring CD4(+)Foxp3(+) regulatory T cells reduces acute graft-versus-host disease lethality without abrogating the graft-versus-leukemia effect in murine models.
    Duramad O; Laysang A; Li J; Ishii Y; Namikawa R
    Biol Blood Marrow Transplant; 2011 Aug; 17(8):1154-68. PubMed ID: 21145405
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Placenta-Derived Decidua Stromal Cells for Treatment of Severe Acute Graft-Versus-Host Disease.
    Ringden O; Baygan A; Remberger M; Gustafsson B; Winiarski J; Khoein B; Moll G; Klingspor L; Westgren M; Sadeghi B
    Stem Cells Transl Med; 2018 Apr; 7(4):325-331. PubMed ID: 29533533
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Cellular therapies for graft-versus-host disease: a tale of tissue repair and tolerance.
    Voermans C; Hazenberg MD
    Blood; 2020 Jul; 136(4):410-417. PubMed ID: 32525970
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Extracellular Vesicles Released from Human Umbilical Cord-Derived Mesenchymal Stromal Cells Prevent Life-Threatening Acute Graft-Versus-Host Disease in a Mouse Model of Allogeneic Hematopoietic Stem Cell Transplantation.
    Wang L; Gu Z; Zhao X; Yang N; Wang F; Deng A; Zhao S; Luo L; Wei H; Guan L; Gao Z; Li Y; Wang L; Liu D; Gao C
    Stem Cells Dev; 2016 Dec; 25(24):1874-1883. PubMed ID: 27649744
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Comparison of Mesenchymal Stromal Cells From Different Origins for the Treatment of Graft-vs.-Host-Disease in a Humanized Mouse Model.
    Grégoire C; Ritacco C; Hannon M; Seidel L; Delens L; Belle L; Dubois S; Vériter S; Lechanteur C; Briquet A; Servais S; Ehx G; Beguin Y; Baron F
    Front Immunol; 2019; 10():619. PubMed ID: 31001253
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Umbilical cord blood-derived mesenchymal stem cells ameliorate graft-versus-host disease following allogeneic hematopoietic stem cell transplantation through multiple immunoregulations.
    Wu QL; Liu XY; Nie DM; Zhu XX; Fang J; You Y; Zhong ZD; Xia LH; Hong M
    J Huazhong Univ Sci Technolog Med Sci; 2015 Aug; 35(4):477-484. PubMed ID: 26223913
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Pharmacologic prophylaxis of acute graft-versus-host disease after allogeneic marrow transplantation.
    Schwinghammer TL; Bloom EJ
    Clin Pharm; 1993 Oct; 12(10):736-61. PubMed ID: 8258255
    [TBL] [Abstract][Full Text] [Related]  

  • 77. [Clinical application of mesenchymal stem cells for hematological diseases].
    Taketani T
    Rinsho Ketsueki; 2018; 59(10):2362-2372. PubMed ID: 30305547
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Antileukemia and antitumor effects of the graft-versus-host disease: a new immunovirological approach.
    Sinkovics JG
    Acta Microbiol Immunol Hung; 2010 Dec; 57(4):253-347. PubMed ID: 21183421
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Impact of bone marrow-derived mesenchymal stromal cells on experimental xenogeneic graft-versus-host disease.
    Bruck F; Belle L; Lechanteur C; de Leval L; Hannon M; Dubois S; Castermans E; Humblet-Baron S; Rahmouni S; Beguin Y; Briquet A; Baron F
    Cytotherapy; 2013 Mar; 15(3):267-79. PubMed ID: 23265769
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Third-party CD4+ invariant natural killer T cells protect from murine GVHD lethality.
    Schneidawind D; Baker J; Pierini A; Buechele C; Luong RH; Meyer EH; Negrin RS
    Blood; 2015 May; 125(22):3491-500. PubMed ID: 25795920
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.